By Greg Brozeit | Posted - Dec 5th, 2021

 

 

 

 

ASH 2021: Focusing on the Big Picture - Meet Kenny Capps

“After my diagnosis, my first stop was to Google everything about the disease,” recalled Kenny Capps, “I don’t recommend that.”

Seven years later, Kenny has had a transplant after receiving induction of Revlimid, Velcade and dexamethasone but has not achieved remission.  He has been on Revlimid maintenance since 2016.

Along the way, he’s come to know a little something about the disease now, which led him to becoming a Myeloma Coach.  “I have been a fitness coach or athlete most of my life, so after meeting Jenny, this felt like a great way to contribute.”

And he’s become more concerned about the big picture of cancer treatment and research.

“Overcoming Barriers for equitable care for myeloma” has become an important issue for Kenny, “myeloma has an unusual imbalance on the racial populations that it affects, so it's super important to address equitable care now.  Minority populations have not only been underserved, but they have been repeatedly lied to and misled.”

With increased attention to disparities, many experts believe understanding and overcoming  disparities in health care access and delivery is a key to achieving cures.  That’s something about which Kenny wants to learn more.

 
Greg Brozeit
About the Author

Greg Brozeit - Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS


Thanks to our Myeloma Crowd Community sponsors:

.                         .       .